Diagnostic value of galectin-3 level in patients with hypertrophic cardiomyopathy

Authors

DOI:

https://doi.org/10.15587/2519-4798.2017.99566

Keywords:

galectin-3, diagnostic value, hypertrophic cardiomyopathy, clinical course, complications, comorbidity

Abstract

The aim of the present research was to study galectin-3 level in patients with hypertrophic cardiomyopathy depending on the disease clinical course, the presence of complications and comorbidity for determination of possibilities of its use as hypertrophic cardiomyopathy biomarker.

Methods. Galectin-3 level was studied in 90 patients with hypertrophic cardiomyopathy with the analysis depending on the disease clinical course, the presence of complications and comorbidity, as well as in 20 patients with cardiac hypertrophy caused by hypertension as the control group.

Results. Galectin-3 level in patients with hypertrophic cardiomyopathy is rather variable and reliably depends on the patients’ age, heart failure severity, and the presence of concomitant third degree hypertension. Besides, there is a tendency to increase galectin-3 level in the presence of atrial fibrillation and after previous myocardial infarction. The correlation between galectin-3 level and hypertrophic cardiomyopathy clinical course peculiarities, the presence of complications and comorbidity points to the limited ability to isolated use of this biomarker for hypertrophic cardiomyopathy diagnostics, but it can be useful for determination of the disease severity and its prognosis.

Conclusion. Galectin-3 level variability indicates the given biomarker’s low diagnostic importance in patients with hypertrophic cardiomyopathy, but its dependence on the disease severity indexes shows galectin-3 predictive value in the mentioned group of patients

The aim of the present research was to study galectin-3 level in patients with hypertrophic cardiomyopathy depending on the disease clinical course, the presence of complications and comorbidity for determination of possibilities of its use as hypertrophic cardiomyopathy biomarker.

Methods. Galectin-3 level was studied in 90 patients with hypertrophic cardiomyopathy with the analysis depending on the disease clinical course, the presence of complications and comorbidity, as well as in 20 patients with cardiac hypertrophy caused by hypertension as the control group.

Results. Galectin-3 level in patients with hypertrophic cardiomyopathy is rather variable and reliably depends on the patients’ age, heart failure severity, and the presence of concomitant third degree hypertension. Besides, there is a tendency to increase galectin-3 level in the presence of atrial fibrillation and after previous myocardial infarction. The correlation between galectin-3 level and hypertrophic cardiomyopathy clinical course peculiarities, the presence of complications and comorbidity points to the limited ability to isolated use of this biomarker for hypertrophic cardiomyopathy diagnostics, but it can be useful for determination of the disease severity and its prognosis.

Conclusion. Galectin-3 level variability indicates the given biomarker’s low diagnostic importance in patients with hypertrophic cardiomyopathy, but its dependence on the disease severity indexes shows galectin-3 predictive value in the mentioned group of patients

Author Biography

Daghar Samaouil, Kharkiv Medical Academy of Postgraduate Education Amosova str., 58, Kharkiv, Ukraine, 61176

Postgraduate student

Department of cardiology and functional diagnostics 

References

  1. Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P. et. al. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35 (39), 2733–2779. doi: 10.1093/eurheartj/ehu284
  2. Chen, Y.-Z., Qiao, S.-B., Hu, F.-H., Yuan, J.-S., Yang, W.-X., Cui, J.-G. et. al. (2015). Left ventricular remodeling and fibrosis: Sex differences and relationship with diastolic function in hypertrophic cardiomyopathy. European Journal of Radiology, 84 (8), 1487–1492. doi: 10.1016/j.ejrad.2015.04.026
  3. Hussain, T., Dragulescu, A., Benson, L., Yoo, S.-J., Meng, H., Windram, J. et. al. (2015). Quantification and Significance of Diffuse Myocardial Fibrosis and Diastolic Dysfunction in Childhood Hypertrophic Cardiomyopathy. Pediatric Cardiology, 36 (5), 970–978. doi: 10.1007/s00246-015-1107-7
  4. Li, A.-H., Liu, P. P., Villarreal, F. J., Garcia, R. A. (2014). Dynamic Changes in Myocardial Matrix and Relevance to Disease: Translational Perspectives. Circulation Research, 114 (5), 916–927. doi: 10.1161/circresaha.114.302819
  5. O’Hanlon, R., Grasso, A., Roughton, M., Moon, J. C., Clark, S., Wage, R. et. al. (2010). Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 56 (11), 867–874. doi: 10.1016/j.jacc.2010.05.010
  6. Lakomkin, S. V., Skvortsov, A. A., Goryunova, T. V., Masenko, V. P., Tereshchenko, S. N. (2012). Galektin-3 – novyy marker diagnostiki i prognoza khronicheskoy serdechnoy nedostatochnosti. Kardiologiya, 3, 45–52.
  7. Li, L.-c., Li, J., Gao, J. (2014). Functions of Galectin-3 and Its Role in Fibrotic Diseases. Journal of Pharmacology and Experimental Therapeutics, 351 (2), 336–343. doi: 10.1124/jpet.114.218370
  8. Yu, X., Sun, Y., Zhao, Y., Zhang, W., Yang, Z., Gao, Y. et. al. (2015). Prognostic Value of Plasma Galectin-3 Levels in Patients With Coronary Heart Disease and Chronic Heart Failure. International Heart Journal, 56 (3), 314–318. doi: 10.1536/ihj.14-304
  9. Wu, C.-K., Su, M.-Y., Lee, J.-K., Chiang, F.-T., Hwang, J.-J., Lin, J.-L. et. al. (2015). Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Scientific Reports, 5, 17007. doi: 10.1038/srep17007
  10. Christenson, R. H., Duh, S.-H., Wu, A. H. B., Smith, A., Abel, G., deFilippi, C. R. et. al. (2010). Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clinical Biochemistry, 43 (7-8), 683–690. doi: 10.1016/j.clinbiochem.2010.02.001
  11. De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2011). The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 272 (1), 55–64. doi: 10.1111/j.1365-2796.2011.02476.x
  12. Lok, D. J. A., Van Der Meer, P., de la Porte, P. W. B.-A., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., van Veldhuisen, D. J. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clinical Research in Cardiology, 99 (5), 323–328. doi: 10.1007/s00392-010-0125-y
  13. Grandin, E. W., Jarolim, P., Murphy, S. A., Ritterova, L., Cannon, C. P., Braunwald, E., Morrow, D. A. (2011). Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clinical Chemistry, 58 (1), 267–273. doi: 10.1373/clinchem.2011.174359
  14. Tseluyko, V. Y., Matviychuk, N. V., Kinoshenko, K. Yu. (2014). Galektin-3 u khvorikh na khronichnu sertsevu nedostatnist. Ukrayins'kyy kardiolohichnyy zhurnal, 3, 77–81.
  15. Tseluyko, V. I., Vashakidze, Z. S., Motylevskaya, T. V., Opolonskaya N. A. (2012). Galektin-3 u bol'nykh s fibrillyatsiyey predserdiy. Ukrayins'kyy kardiolohichnyy zhurnal, 3, 45–49.
  16. Tseluyko, V. I., Zhadan, A. V., Zedginidze, E. (2015). Galektin-3 i obratnoye remodelirovaniye serdtsa posle khirurgicheskoy korrektsii nedostatochnosti mitral'nogo klapana. Ukrayins'kyy kardiolohichnyy zhurnal, 6, 79–82.

Downloads

Published

2017-04-29

How to Cite

Samaouil, D. (2017). Diagnostic value of galectin-3 level in patients with hypertrophic cardiomyopathy. ScienceRise: Medical Science, (4 (12), 13–18. https://doi.org/10.15587/2519-4798.2017.99566

Issue

No. 4 (12) (2017)

Section

Medical Science

License

Copyright (c) 2017 Daghar Samaouil

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.